Thu, Apr 24, 2014, 10:19 AM EDT - U.S. Markets close in 5 hrs 41 mins


% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

  • jcmoneystox jcmoneystox May 15, 2013 8:32 PM Flag

    Statistically significant survival benefit

    will be presented at ASCO for 2nd line NSCLC. Amazing that an 11.7 month MOS was reported with only 54% of patients in the 3mg/kg arm had passed. To be conservative, lets assume the remaining 46% passed away the day PPHM reported its results on Feb 19. That puts the remaining 46% of patients at a minimum of 16 months since enrollment was completed in October 2011. The final MOS for the 3mg/kg arm in 2nd line NSCLC will be greater than 12 months. That is amazing. I only hope they try to drop the PPS tomorrow as I will be adding substantially.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The MOS will not change. I think people are confusing median with mean or average.

      Sentiment: Strong Buy

      • 1 Reply to trademerk
      • "3 mg/kg B in combination with D was well tolerated and is the planned dose for Phase 3." The key here is the word "Phase 3"....Sounds like progression to Phase 3 is right around the corner and we now know the final MOS for the 3mg/kg are will be 12 months...I don't play the games on these boards like some the cracker jacks who post every 5 minutes "wook wook" everything, I look at the science and have a stop-loss in at $1.15, so worse case I double my money and who knows what the upside could be with the right PR

        Sentiment: Buy

1.77-0.07(-3.80%)10:18 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.